TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02141061
Drug: Telapristone Acetate, Proellex 12 mg Formulation A
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02141061
Drug: Telapristone Acetate, Proellex 12 mg Formulation B
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00140803
Drug: Visudyne
Normalized name: Visudyne
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00140803
Drug: Kenalog
Normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00815360
Drug: intravitreal injection of triamcinolone acetonide
Normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravitreal injection of 4.0 mg triamcinolone acetonide
Study: NCT01462773
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
Study: NCT01035190
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhalation, 200 µg/puff
Study: NCT04484350
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
Study: NCT04484350
Drug: Hydralazine
Normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
Study: NCT04484350
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 - 2.5 mg IV bolus and then q6h PRN.
Study: NCT00701987
Drug: ALS-357
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ALS-357
Study: NCT00634231
Drug: valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01355289
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01355289
Drug: Pegylated interferon (PEG-IFN)
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
Study: NCT01355289
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study: NCT01355289
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
Study: NCT01447394
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Study: NCT04727671
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study: NCT04727671
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
Study: NCT04727671
Drug: Human Chorionic Gonadotropin (hCG)
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study: NCT06117514
Drug: Sudapyridine 30mg
Normalized name: Sulfapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudapyridine capsule 30mg, orally, single dose
Study: NCT06117514
Drug: Sudapyridine 100mg SAD
Normalized name: Sulfapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudapyridine tablet, 100mg orally, single dose
Study: NCT06117514
Drug: Sudapyridine 200mg SAD
Normalized name: Sulfapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudapyridine tablet, 200mg orally, single dose
Study: NCT06117514
Drug: Sudapyridine 200mg MAD
Normalized name: Sulfapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudapyridine tablet, 200mg orally once a day for 14 days
Study: NCT06117514
Drug: Sudapyridine 300mg MAD
Normalized name: Sulfapyridine
DrugBank: Sudapyridine (DB18984)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudapyridine tablet, 300mg orally once a day for 14 days
Study: NCT02938182
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel troche 75 mg daily for three months
Study: NCT00541983
Drug: XOMA 052
Normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
Study: NCT03690154
Drug: FN-1501
Normalized name: FN-1501
DrugBank: FN-1501 (DB17383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
Study: NCT00470496
Drug: HPPH
Normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01865292
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
Study: NCT01865292
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
Study: NCT02589977
Drug: regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
Study: NCT01470677
Drug: Tachosil fibrin patch
Normalized name: fibrinogen / thrombin Medicated Patch [TachoSil]
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
Study: NCT00619957
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
Study: NCT01508455
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01508455
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01508455
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01462773
Drug: Interferon Alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
Study: NCT04417257
Drug: LAU-7b
Normalized name: 3a,6b,7b,12a-(OH)4-5b-cholanic acid
DrugBank: 3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic acid (DB18044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
Study: NCT00815646
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
Study: NCT00078130
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00116025
Drug: Human acylated ghrelin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02036229
Drug: ivermectin cream 0.5%
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
Study: NCT02604004
Drug: Lamivudine 150-mg tablet single dose (drug test)
Normalized name: lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study: NCT03534037
Drug: Febuxostat 40 mg
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40 mg orally per day plus dietary control only
Study: NCT03534037
Drug: Benzbromarone 50mg
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 50mg orally per day plus dietary control only
Study: NCT00024687
Drug: SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin
Normalized name: anti-CD11a
DrugBank: SS1(dsFv)-PE38 (DB17579)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420030
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
Study: NCT01147809
Drug: Eltrombopag olamine
Normalized name: Eltrombopag Olamine
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: thrombopoietin receptor agonist
Study: NCT02820961
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An orally available histone deacetylases inhibitor (HDAC)
Study: NCT02820961
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitor
Study: NCT01956006
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
Study: NCT01159262
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
Study: NCT01159262
Drug: Fentanyl/Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per package insert, N-PASS scores and investigator discretion.
Study: NCT01159262
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00312130
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01526148
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
Study: NCT01526148
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
Study: NCT02107144
Drug: trimetazidine
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
Study: NCT00227357
Drug: On-site - buprenorphine/naloxone (Suboxone)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, sub-lingual, 8/2 mg, 1-3 daily
Study: NCT00227357
Drug: Off-site - methadone or no agonist
Normalized name: Off! Explore
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00482846
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;
Study: NCT02137668
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Vancomycin is given to PSC or BA participants
Study: NCT02953041
Drug: Glycopyrronium
Normalized name: glycopyrronium
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-acting muscarinic antagonist
Study: NCT02953041
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ultra long-acting beta agonist
Study: NCT03553394
Drug: Ringer's Acetate
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
Study: NCT04070794
Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
Study: NCT04070794
Drug: Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
Study: NCT03609060
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
Study: NCT00302224
Drug: 2S, 4R Ketoconazole (DIO-902)
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01353339
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg, PO, once daily for 3 months
Study: NCT02387021
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02387021
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01075321
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT01075321
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT00099697
Drug: DHEA
Normalized name: DHEA
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01923181
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-daily oral administration as tablets.
Study: NCT01923181
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
Study: NCT00164801
Drug: Baclofen, Diltiazem
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00265655
Drug: Satraplatin
Normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
Study: NCT00710385
Drug: Heroin
Normalized name: Heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (25 mg)
Study: NCT00710385
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .4 mg
Study: NCT01253603
Drug: Fluticasone propionate inhaler twice daily for 28 days
Normalized name: fluticasone propionate Inhalant Product
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00749190
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00749190
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00211003
Drug: doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00710385
Drug: Low Bup Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 and 8 mg
Study: NCT01575561
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20-80 mg taken orally once daily
Study: NCT00774787
Drug: imiquimod 5% cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 packet (250 mg cream) 3 times per week for 4 weeks
Study: NCT02554773
Drug: Fitusiran (SAR439774)
Normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
Study: NCT00633984
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Study: NCT00710385
Drug: High Bup Dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg and 16 mg
Study: NCT02839694
Drug: decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study: NCT02839694
Drug: Tetrahydrouridine (THU)
Normalized name: (4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
Study: NCT00409344
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
Study: NCT00120601
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00120601
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03035760
Drug: Oxfendazole
Normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
Study: NCT00144170
Drug: Tipranavir (with low dose ritonavir)
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no